News Is J&J approaching the end of its talc litigation hangover? Johnson & Johnson has made a $5.5bn bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close.
News Re-rostered FDA committee backs peptide compounding Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.
News EU warns of brain tumour risk with some contraceptives EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
R&D Bridging ethics and efficacy in IRB review of vaccine trials Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.
Oncology CAR-NK cell therapies for solid tumours: Closing the gap bet... CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.